Table 4.

Questions not answered by the PACIFIC trial (testing durvalumab after the completion of concurrent chemoradiation in patients with unresectable and inoperable stage III lung cancers)

• Applicability of the PACIFIC data to other population of patients?

• Resectable disease

• PS2

• Elderly

• Individuals receiving sequential chemoradiotherapy

• Patients with EFGR L858R and exon 19 deletion mutations

• Can durvalumab be safely prescribed in patients who have received a high radiation dose to thoracic organs at risk (e.g. lung)?

• Can we create precise definitions of “operable and resectable”? How is this assessment best obtained?

• How soon should durvalumab start after CTRT?

• What is the optimal duration of durvalumab?

• What is the optimal timing durvalumab and CTRT: concomitant or sequential?

• Should we treat patients with durvalumab if PDL1 <1%?

• Do biomarkers exist to better select patients?